Crutch Sebastian J, Schott Jonathan M, Rabinovici Gil D, Murray Melissa, Snowden Julie S, van der Flier Wiesje M, Dickerson Bradford C, Vandenberghe Rik, Ahmed Samrah, Bak Thomas H, Boeve Bradley F, Butler Christopher, Cappa Stefano F, Ceccaldi Mathieu, de Souza Leonardo Cruz, Dubois Bruno, Felician Olivier, Galasko Douglas, Graff-Radford Jonathan, Graff-Radford Neill R, Hof Patrick R, Krolak-Salmon Pierre, Lehmann Manja, Magnin Eloi, Mendez Mario F, Nestor Peter J, Onyike Chiadi U, Pelak Victoria S, Pijnenburg Yolande, Primativo Silvia, Rossor Martin N, Ryan Natalie S, Scheltens Philip, Shakespeare Timothy J, Suárez González Aida, Tang-Wai David F, Yong Keir X X, Carrillo Maria, Fox Nick C
Dementia Research Centre, UCL Institute of Neurology, London, UK.
Dementia Research Centre, UCL Institute of Neurology, London, UK.
Alzheimers Dement. 2017 Aug;13(8):870-884. doi: 10.1016/j.jalz.2017.01.014. Epub 2017 Mar 2.
A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings.
Consensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA.
A three-level classification framework for PCA is described comprising both syndrome- and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum.
There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work.
提出了一种后皮质萎缩(PCA)的分类框架,以提高该综合征在各种研究环境中定义的一致性。
通过详细的文献综述、成立一个四次召开会议的国际多学科工作组以及一项关于症状频率和PCA概念化的基于网络的定量调查,制定了关于PCA的共识声明。
描述了一种PCA的三级分类框架,包括综合征层面和疾病层面的描述。分类级别1(PCA)定义了临床放射学综合征的核心临床、认知和神经影像学特征及排除标准。分类级别2(单纯PCA、伴其他特征的PCA)确定除了核心PCA综合征外,是否存在任何其他神经退行性综合征的核心特征。分类级别3(由阿尔茨海默病引起的PCA [PCA-AD]、路易体病 [PCA-LBD]、皮质基底节变性 [PCA-CBD]、朊病毒病 [PCA-朊病毒])基于现有的病理生理学生物标志物证据,对PCA综合征的潜在病因进行更正式的判定。针对定义综合征严重程度阶段和描述PCA谱系内表型异质性的挑战,讨论了额外的综合征层面描述符问题。
对于核心临床放射学综合征的定义存在强烈共识,这意味着当前的共识声明应被视为对先前单中心PCA标准的细化、发展和扩展,而非对该综合征的任何全面改变或重新描述。该框架和术语可能有助于跨研究解释研究数据,适用于广泛的研究场景(如行为干预、药物试验),并为未来的合作工作提供基础。